Los Angeles Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Los Angeles Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,159	Closed	-$212K	–	1419
2019 Q2	$212K	Buy	+10,159	New	+$209K	﹤0.01%	1281
2018 Q4	–	Sell	-36,781	Closed	-$1M	–	1437
2018 Q3	$1M	Sell	36,781 -38,344	-51%	-$1.08M	0.01%	872
2018 Q2	$2.02M	Buy	75,125 +43,020	+134%	+$1.32M	0.01%	690
2018 Q1	$1.02M	Buy	+32,105	New	+$1.13M	0.01%	821

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Los Angeles Capital Management's AIMT Position: Q3 2019 in Review

Los Angeles Capital Management sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 10,159 shares — an estimated $212K sold.

Los Angeles Capital Management first reported a position in AIMT in Q1 2018 and held it in 4 quarters. The position peaked at $2.02M in Q2 2018. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

Los Angeles Capital Management reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
Los Angeles Capital Management sold 10,159 Aimmune Therapeutics shares in Q3 2019, an estimated $212K.
Los Angeles Capital Management first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 4 quarters.
Los Angeles Capital Management's Aimmune Therapeutics position peaked at $2.02M in Q2 2018.
146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Los Angeles Capital Management's 13F filing for Q3 2019, filed 7 Nov 2019.